Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LogicBio Therapeutics, Inc.LOGC · Entity 122292 | General Counsel and Secretary | March 01, 2022 | March 03, 2022 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Legal Officer | February 03, 2025 | February 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LogicBio Therapeutics, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2032-03-01 | Direct | 80,000 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 80,000 · Balance 80,000 F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.
Zentalis Pharmaceuticals, Inc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,070,784 |
Ending reported balance
After 2025-02-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-03 · Grant · Acquired 934,041 · Balance 1,084,014 F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2025-02-03 · Sale · Disposed 13,230 · Balance 1,070,784 F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2035-02-02 | Direct | 124,714 |
Reported balance
After 2025-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-03 · Grant · Acquired 124,714 · Balance 124,714 F3: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F3: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 5, 2025 18:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 124,714 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001725160-25-000040 · wk-form4_1738798313.xml · derivative · entry 3 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,714 Underlying: Common Stock · 124,714 shares Expires 2035-02-02 F3 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,230 | $1.71 | $22,643.15 |
DisclosureSEC source: 0001725160-25-000040 · wk-form4_1738798313.xml · nonDerivative · entry 2 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,784 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:31 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 934,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000040 · wk-form4_1738798313.xml · nonDerivative · entry 1 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,084,014 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,310 | $11.54 | $38,197.40 |
DisclosureSEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · nonDerivative · entry 2 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,973 F2 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · derivative · entry 4 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-31 F5 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's promotion to Chief Legal Officer, which became effective February 1, 2024. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · derivative · entry 3 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Legal Officer, a role to which she was promoted on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000032 · wk-form4_1707178473.xml · nonDerivative · entry 1 Paul Andrea · CIK 0001863130 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,283 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 01, 2023 Filed Feb 1, 2023 19:06 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 59,217 | $0.00 Strike: $23.65 | $0.00 |
DisclosureSEC source: 0001725160-23-000016 · wf-form4_167529638915918.xml · derivative · entry 2 Paul Andrea · CIK 0001863130 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,217 Underlying: Common Stock · 59,217 shares Expires 2033-01-31 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 1, 2023 19:06 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 40,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000016 · wf-form4_167529638915918.xml · nonDerivative · entry 1 Paul Andrea · CIK 0001863130 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,783 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 17:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 290,500 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001725160-22-000142 · wf-form4_165938928345083.xml · derivative · entry 1 Paul Andrea · CIK 0001863130 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,500 Underlying: Common Stock · 290,500 shares Expires 2032-07-31 F1 · derivative.exercise_date: The options were granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:09 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-22-015817 · doc4.xml · derivative · entry 1 Paul Andrea · CIK 0001863130 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-03-01 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 16:12 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantEmployee Stock Option (Right to buy) · Derivative | 165,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-21-033994 · doc4.xml · derivative · entry 1 Paul Andrea · CIK 0001863130 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2031-05-17 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.